Roche
Roche changes raise Novartis takeover question
March 29, 2011Sales and Marketing Novartis, Roche, mergers and acquisitions
Roche could be vulnerable to a takeover from its Swiss rival Novartis after changes in its boardroom. The Roche family …
Roche’s skin cancer drug passes mid-stage trial
March 22, 2011Research and Development Curis, Roche, advanced basal cell carcinoma, skin cancer, vismodegib
Roche’s skin cancer candidate vismodegib has met its primary endpoint in a phase II trial. The drug is being tested …
Bayer-helmed oncology biomarker project launched
March 14, 2011Manufacturing and Production, Research and Development AstraZeneca, Bayer, Janssen, Max Planck Institute, Merck, OncoTrack, Pfizer, Roche, biomarkers, oncology
A project to develop the next generation of oncology biomarkers has been launched in Berlin. The pharma industry and European …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
Roche pulls out of vaccine alliance with Transgene
February 23, 2011Research and Development HPV, HPV vaccine, Roche, TG4001, Transgene, cervical cancer, cervical lesions, human papilloma virus, vaccines
Roche has terminated its license agreement with Transgene for its HPV therapeutic vaccine TG4001. The vaccine is currently being tested …
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Survey shows doctors support FDA Avastin decision
February 7, 2011Sales and Marketing FDA, Roche, Sermo, avastin, bevacizumab
A survey of US doctors suggests that a majority support the FDA’s decision to take away Avastin’s licence for use …
Roche weathers tough year and looks to pipeline for 2011
February 3, 2011Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab
Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …
Diabetes success for Sanofi, disappointment for Roche
February 2, 2011Roche, Sanofi, diabetes
The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …
Tarceva set for first line treatment
January 31, 2011Sales and Marketing Iressa, NSCLC, Roche, Tarceva
Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …
Bio and clinical plants feature in 2011 FOYA honours
January 25, 2011Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing
Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …
Trial success for Roche’s personalised skin cancer drug
January 19, 2011Research and Development BRAF V600, Cancer, RG7204, Roche, personalised medicine, skin cancer
A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …
Roche finance chief steps down
January 17, 2011Sales and Marketing Alan Hippe, Erich Hunziker, Roche, appointment, sales and marketing
Roche’s chief financial officer Erich Hunziker is to retire at the end of March after ten years with the company. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
